CARDIOVASCULAR JOURNAL OF AFRICA • Vol 23, No 6, July 2012
AFRICA
335
22. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ,
et al
. Leptin regulates proinflammatory immune responses.
FASEB J
1998;
12
: 57–65.
23. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin
enhances the calcification of vascular cells: artery wall as a target of
leptin.
Circ Res
2001;
88
: 954–960.
24. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-
dependent platelet aggregation and arterial thrombosis suggests a
mechanism for atherothrombotic disease in obesity.
J Clin Invest
2001;
108
: 1533–1540.
25. Corsonello A, Perticone F, Malara A, De Domenico D, Loddo S, Buemi
M,
et al.
Leptin-dependent platelet aggregation in healthy, overweight
and obese subjects.
Int J Obes Relat Metab Disord
2003;
27
: 566–573.
26. Sundell J, Huupponen R, Raitakari OT, Nuutila P, Knuuti J. High serum
leptin is associated with attenuated coronary vasoreactivity.
Obes Res
2003;
11
: 776–782.
27. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee
M. Leptin induces mitochondrial superoxide production and monocyte
chemoattractant protein-1 expression in aortic endothelial cells by
increasing fatty acid oxidation via protein kinase A.
J Biol Chem
2001;
276
: 25096–25100.
28. Shirasaka T, Takasaki M, Kannan H. Cardiovascular effects of leptin
and orexins.
Am J Physiol Regul Integr Comp Physiol
2003;
284
:
R639–R651.
29. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon
P,
et al.
Plasma leptin is independently associated with the intima-media
thickness of the common carotid artery.
Int J Obes Relat Metab Disord
2001;
25
: 805–810.
30. Iribarren C, Husson G, Go AS, Lo JC, Fair JM, Rubin GD,
et al.
Plasma
leptin levels and coronary artery calcification in older adults.
J Clin
Endocrinol Metab
2006;
92
(2): 729–732.
31. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR,
et
al
. Plasma leptin levels are associated with coronary atherosclerosis in
type 2 diabetes.
J Clin Endocrinol Metabol
2004;
89
(8): 3872–3878.
32. Couillard C, Lamarche B, Mauriege P, Cantin B, Dagenais GR,
Moorjani S,
et al
. Leptinemia is not a risk factor for ischemic heart
disease in men. Prospective results from the Quebec Cardiovascular
Study.
Diabetes Care
1998;
21
: 782–786.
33. Rajappa M, Mallika V, Goswami B, Pagare V. Role of inflammation
and infection in acute coronary syndromes-a review.
International Med
J
2004;
11
: 385–390.
34. Goswami B , Rajappa M, Mallika V, Shukla DK, Kumar S. TNF-
α
/
IL-10 ratio and C-reactive protein as markers of the inflammatory
response in CAD-prone North Indian patients with acute myocardial
infarction.
Clinica Chimica Acta
2009;
408
: 14–18.
35. Martín-Venturaa JL, Blanco-Colioa LM, Tuñónb J, Muñoz-Garcíaa B,
Madrigal-Matutea J, Morenoa JA,
et al
. Biomarkers in cardiovascular
medicine. Update.
Rev Exp Cardiol
2009;
62
(6): 677–688.
36. Koenig W. Is hsCRP back on board? Implications from the JUPITER
trail.
Clin Chem
2009;
55
(2): 216–218.
37. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman
S,
et al.
Inflammation, pravastatin, and the risk of coronary events
after myocardial infarction in patients with average cholesterol levels.
Cholesterol and Recurrent Events (CARE) Investigators.
Circulation
1998;
98
: 839–844.
38. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS,
et al
.
Measurement of C-reactive protein for the targeting of statin therapy in
the primary prevention of acute coronary events.
N Engl J Med
2001;
344
: 1959–1965.
39. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.
Inflammation, aspirin, and the risk of cardiovascular disease in appar-
ently healthy men.
N Engl J Med
1997;
33
6: 973–979.
40. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V,
et al
. C-reactive
protein as a screening test for cardiovascular risk in a multiethnic popu-
lation.
Arterioscler Thromb Vasc Biol
2004;
24
: 1509–1515.
41. Yusuf S, Hawken S, Ounpuu S, Dans T, AvezumA, Lanas F,
et al
. Effect
of potentially modifiable risk factors associated with myocardial infarc-
tion in 52 countries (the INTERHEART study): case-control study.
Lancet
2004;
36
4: 937–952.
42. Cosin-Sales J, Christiansen M, Kaminski P, Oxvig C, Overgaard
MT, Cole D,
et al.
Pregnancy-Associated Plasma Protein A and its
endogenous inhibitor, the proform of Eosinophil Major Basic Protein
(proMBP), are related to complex stenosis morphology in patients with
stable angina pectoris.
Circulation
2004;
10
9: 1724–1728.
43. Aso Y, Okumura K, Wakabayashi S, Ki KT, Taki S, Inuka T. Elevated
pregnancy-associated plasma protein-A in sera from type 2 diabetic
patients with hypercholesterolemia: associations with carotid athero-
sclerosis and toe-brachial index.
J Clin Endocrinol Metab
2004;
89
(11):
5713–5717.
44. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ,
Hays LG,
et al.
The insulin-like growth factor (IGF)-dependent IGF
binding protein-4 protease secreted by human fibroblasts is pregnancy-
associated plasma protein-A.
Proc Natl Acad Sci USA
1999;
96
:
3149–3153.
45. Renier G, Clement I, Desfaits AC, Lambert A. Direct stimulatory
effect of insulin-like growth factor-I on monocyte and macrophage
tumor necrosis factor-alpha production.
Endocrinology
1996;
137
:
4611–4618.
46. Hochberg Z, Hertz P, Maor G, Oiknine J, Aviram M. Growth hormone
and insulin-like growth factor-I increase macrophage uptake and degra-
dation of low density lipoprotein
. Endocrinology
1992;
131
: 430–435.
47. Jones JI, Prevette T, Gockerman A, Clemmons DR. Ligand occupancy
of the V3 integrin is necessary for smooth muscle cells to migrate in
response to insulin-like growth factor.
Proc Natl Acad Sci USA
1996;
93
: 2482–2487.
48. Qin QP, Wittfooth S, Pettersson K. Measurement and clinical signifi-
cance of circulating PAPP-A in ACS patients.
Clin Chim Acta
2007;
380
(1–2): 59–67.
49. Miedema MD, Conover CA, MacDonald H, Harrington SC, Oberg D,
Wilson D,
et al
. Pregnancy-associated plasma protein-A elevation in
patients with acute coronary syndrome and subsequent atorvastatin
therapy.
Am J Cardiol
2008;
101
(1): 35–39.
50. Lund J, Qin QP, Ilva T, Pettersson K, Voipio-Pulkki LM, Porela P,
et al.
Circulating pregnancy-associated plasma protein A predicts outcome
in patients with acute coronary syndrome but no troponin I elevation.
Circulation
2003;
108
: 1924–1926.
51. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML,
Zeiher AM; CAPTURE Study Investigators. Pregnancy-associated
plasma protein-A levels in patients with acute coronary syndromes:
comparison with markers of systemic inflammation, platelet activation,
and myocardial necrosis.
J Am Coll Cardiol
2005;
45
(2): 229–237.
52. Elesber AA, Conover CA, Denktas AE, Lennon RJ, Holmes DR,
Overgaard MT,
et al.
Prognostic value of circulating pregnancy-asso-
ciated plasma protein levels in patients with chronic stable angina.
Eur
Heart J
2006;
27
: 1678–1684.
53. Beaudeux JL, Burc L, Imbert-Bismut F, Giral P, Bernard M, Bruckert E,
et al.
Serum plasma pregnancy-associated protein A: a potential marker
of echogenic carotid atherosclerotic plaques in asymptomatic hyper-
lipidemic subjects at high cardiovascular risk.
Arterioscler Thromb Vasc
Biol
2003;
23
: e7–10.
54. Hájek P, Macek M, Hladíková M, Houbová B, Alan D, Durdil V,
et
al
. Pregnancy-associated plasma protein A and proform eosinophilic
major basic protein in the detection of different types of coronary artery
disease.
Physiol Res
2008;
57
: 23–32.
55. Crea F, Andreotti F. Pregnancy associated plasma protein-A and coro-
nary atherosclerosis: marker, friend, or foe?
Eur Heart J
2005;
26
:
2075–2076.
56. Mueller T, Dieplinger B, Poelz W, Haltmayer M. Increased pregnancy-
associated plasma protein-A as a marker for peripheral atherosclerosis:
results from the Linz Peripheral Arterial Disease Study.
Clin Chem
2006;
52
(6): 1096–1103.
57. Jin-lai L, Hui Z, Xu-jing X, Lin C, Chang-lin Z. Changes of pregnancy-
associated plasma protein-A in patients with acute coronary syndrome.
Chinese Med J
2005;
118
(21): 1827–1829.
58. Sikari KA. The clinical biochemistry of obesity
. Clin Biochem Rev
2004;
25
(3): 165–181.
59. Mathieu P, Pibarot P, Després JP. Metabolic Syndrome: the danger
signal in atherosclerosis.
Vasc Health Risk Manag
2006;
2
(3): 285–302.
